Epclusa Tablet, Film Coated
Product Images NDC 61958-2201

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Epclusa (NDC 61958-2201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Epclusa 01)

FDA Label Image

Chemical Structure (Epclusa 02)

FDA Label Image

Principal Display Panel (28 Tablet Bottle Label)

FDA Label Image

Epclusa 04

FDA Label Image

Epclusa 05

FDA Label Image

Epclusa 06

FDA Label Image

Epclusa 07

FDA Label Image

Epclusa 08

FDA Label Image

Epclusa 09

FDA Label Image

Epclusa 10

FDA Label Image

Epclusa 11

FDA Label Image

Epclusa 12

Epclusa tablets contain 400mg of sofosbuvir and 100mg of velpatasvir. They should be stored below 30°C (86°F) and dispensed only in the original container. The package insert provides information about dosage and administration. The tablets are manufactured by Gilead Sciences, Inc. in Ireland. They are available in a package of 28 tablets and should be taken once daily. There is an ALERT box on the package that should not be covered by a pharmacy label. Information about medicines that should not be taken with Epclusa is available.*

FDA Label Image

Epclusa 13

Epclusa tablets contain 200mg of sofosbuvir and 50mg of velpatasvir per tablet, with each bottle containing 28 tablets. The recommended storage temperature is below 30°C (86°F). The tablets must only be dispensed in their original container. The recommended dosage must be taken as per the prescribing information. Epclusa is manufactured for Gilead Sciences, Inc., based in Foster City, CA 94404, and made in Canada. This text refers only to Epclusa® (sofosbuvir and velpatasvir) tablets.*

FDA Label Image

Epclusa 14

This text is a product description for Epclusa oral pellets used for the treatment of Hepatitis C. The recommended dosage is one packet containing 200mg/50mg oral pellets which should be swallowed whole without being chewed. Additionally, there is a warning to pharmacy staff not to cover the ALERT on the packaging with a pharmacy label. The product is manufactured by Gilead.*

FDA Label Image

Epclusa 15

Reonly P is a medication available as oral pellets containing 150mg of sofosbuvir and 37.5mg of velpatasvir per packet. The medication should be swallowed whole and should not be chewed. Reonly P is manufactured by Gilead.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.